Flutiform in Treatment of Patients With Asthma in Daily Clinical Practice.

Mundipharma Pharmaceuticals B.V.

Overview

The objective of the study is to evaluate the effect of frequency of use with a spacer on asthma control in Dutch patients with asthma during their daily clinical practice over 12 weeks treatment.

Study Type

OBSERVATIONAL

Conditions

Asthma

Interventions

Observational. Non interventional studyOTHER

Observational. Non interventional study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients eligible to be prescribed fluticasone/formoterol fixed dose combination as follows: Patients not adequately controlled in inhaled corticosteriods and "as required" inhaled short acting beta 2 agonist or patients already adequately controlled on both an inhaled corticosteriod and a long-acting beta 2 agonist. The decision to prescribe fluticasone/formoterol fixed dose combination will precede and be independent of the decision to enroll the patient into the study Exclusion Criteria: * There are no specific exclusion criteria as this is an observational study

Outcomes

Primary Outcomes

Evaluate the effect of frequency of spacer use on asthma control in patients in normal clinical practice

the Asthma Control Questionnaire will be completed by subjects at study baseline and then after 12 weeks of treatment. Difference between the 2 will be the primary endpoint.

Time frame: This measurement will be taken after 12 weeks of treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.